Aquestive Therapeutics, Inc. (AQST)
About Aquestive Therapeutics, Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $44.5M
- Net income
- -$83.8M
- Total assets
- $160.4M
- Market cap
- $493.0M
- Gross margin
- 58.3%
- Operating margin
- -159.5%
- Net margin
- -188.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $44.5M
- Cost of revenue
- $18.6M
- Gross profit
- $26.0M
- Operating expenses
- $97.0M
- Operating income
- -$71.1M
- Income tax
- $0
- Net income
- -$83.8M
- EPS (basic)
- $-0.78
- EPS (diluted)
- $-0.78
Balance sheet
- Total assets
- $160.4M
- Current assets
- $149.3M
- Total liabilities
- $194.1M
- Current liabilities
- $47.6M
- Shareholders’ equity
- -$33.7M
Cash flow
- Operating cash flow
- -$52.4M
- Investing cash flow
- -$562.0K
- Financing cash flow
- $102.6M
- Net cash flow
- $49.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $493.0M
- EPS (diluted)
- $-0.78
- Shares outstanding
- 134.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 25, 2018
Aquestive Therapeutics, Inc. (AQST) Stock Price
- Reported a net loss of $83.8M in FY2025.
- Revenue declined 12% from FY2021 to FY2025.
- Gross margin of 58.3%, net margin -188.1%.
- Trading 51% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Aquestive Therapeutics, Inc..
Write a review
News about Aquestive Therapeutics, Inc.
News & sentiment via Polygon.io
Aquestive Therapeutics, Inc.: frequently asked questions
Is Aquestive Therapeutics, Inc. an American company?
Aquestive Therapeutics, Inc. is a US-based company headquartered in Warren, New Jersey, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Aquestive Therapeutics, Inc. headquartered?
Aquestive Therapeutics, Inc. is headquartered in Warren, New Jersey, United States.
Is Aquestive Therapeutics, Inc. publicly traded?
Yes — Aquestive Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol AQST on the NASDAQ.
What does Aquestive Therapeutics, Inc. do?
Aquestive Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
